FDA Staff Scientists Disagree with Advisory Panel on Compounded Peptides

FDA staff scientists are in opposition to an advisory panel's recommendation to ease access to compounded peptides, creating uncertainty about the agency's future actions.

2 Aug, 12:49 — 2 Aug, 12:49

Post Share

Sources

Showing 1 of 1 sources

forbes4h ago

On Peptides, FDA Staff Scientists At Odds With Advisory Panel

Though FDA would normally follow a panel’s advice to move ahead with compounded peptides, it’s unclear how it will act, because FDA staff are opposed to easing access.

By Joshua P. Cohen, Senior Contributor

Read full article →

PERSPECTA

PERSPECTA

FDA Staff Scientists Disagree with Advisory Panel on Compounded Peptides

Sources

On Peptides, FDA Staff Scientists At Odds With Advisory Panel

Related Stories

Utrecht University Investigates Professor for Personal Payments from Companies

Influence of Foreign Banks on Economy in Kingdom of Yugoslavia

European Commission Approves First Oral GLP-1 Weight-Loss Drug

Iran War Drives Up Street Food Prices Across Asia

PERSPECTA